Immunotherapy is one of the key strategies for cancer treatment. The cGAS-cGAMP-STING-IRF3 pathway of cytosolic DNA sensing plays a pivotal role in antiviral defense. We report that the STING activator cGAMP possesses significant antitumor activity in mice by triggering the STING-dependent pathway directly. cGAMP enhances innate immune responses by inducing production of cytokines such as interferon-, interferon-, and stimulating dendritic cells activation, which induces the cross-priming of CD8(+) T cells. The antitumor mechanism of cGAMP was verified by STING and IRF3, which were up-regulated upon cGAMP treatment. STING-deficiency dramatically reduced the antitumor effect of cGAMP. Furthermore, cGAMP improved the antitumor activity of 5-FU, and clearly reduced the toxicity of 5-FU. These results demonstrated that cGAMP is a novel antitumor agent and has potential applications in cancer immunotherapy.
Sci Rep
- Apoptosis
- Interferon Regulatory Factor-3
- Mice, Inbred BALB C
- Antineoplastic Agents
- Animals
- Nucleotides, Cyclic
- Cytokines
- Cell Line, Tumor
- Immunity, Innate
- Dendritic Cells
- Fluorouracil
- Membrane Proteins
- Nucleotidyltransferases
16.25
150